Related references
Note: Only part of the references are listed.Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
Christian Recher et al.
LEUKEMIA (2022)
Reality check: Real-world evidence to support therapeutic development in hematologic malignancies
Benjamin A. Derman et al.
BLOOD REVIEWS (2022)
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
Eleonora De Bellis et al.
LEUKEMIA RESEARCH (2022)
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
Pau Montesinos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Amer M. Zeidan et al.
FUTURE ONCOLOGY (2021)
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
Hagop Kantarjian et al.
LANCET HAEMATOLOGY (2021)
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Christoph Roellig et al.
BLOOD (2020)
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Amer M. Zeidan et al.
BLOOD ADVANCES (2020)
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience
Sara Pepe et al.
ANNALS OF HEMATOLOGY (2020)
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Rory M. Shallis et al.
BLOOD REVIEWS (2019)
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy
Monica Bocchia et al.
HEMATOLOGICAL ONCOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia
Amanda C. Winters et al.
BLOOD ADVANCES (2019)
A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine
Lauren B. Levine et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study)
Juergen Wehmeyer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
Pin-Fang He et al.
ONCOTARGET (2017)
Senescent Nephropathy: The New Renal Syndrome
Florencia Aiello et al.
HEALTHCARE (2017)
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices
Esprit Ma et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study
Jianming He et al.
LEUKEMIA & LYMPHOMA (2015)
The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure
Mattia A. E. Valente et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Survival for older patients with acute myeloid leukemia: a population-based study
Betul Oran et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency
G. Nicolas Batty et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
